Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18953636 | 0.87 | CREBBP (0.48) | CREBBPTDP1NOS1HTTPOLB | |
| SCHEMBL18953635 | 0.87 | CREBBP (0.48) | CREBBPTDP1NOS1HTTPOLB | |
| SCHEMBL1856772 | 0.85 | CREBBP (0.47) | CREBBPTDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL6066037 | 0.82 | CREBBP (0.45) | CREBBPTDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1861487 | 0.81 | CREBBP (0.44) | CREBBPTDP1NOS1HTTPOLB | |
| SCHEMBL29510797 | 0.81 | CREBBP (0.44) | CREBBPTDP1NOS1HTTALDH1A1 | |
| SCHEMBL2481191 | 0.81 | CREBBP (0.44) | CREBBPTDP1NOS1HTTALDH1A1 | |
| SCHEMBL27632906 | 0.79 | CREBBP (0.44) | CREBBPTDP1NOS1HTTPOLB | |
| SCHEMBL1863124 | 0.79 | CREBBP (0.42) | CREBBPTDP1NOS1HTTALDH1A1 | |
| SCHEMBL6066042 | 0.79 | CREBBP (0.42) | CREBBPTDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483366-B | Indole compound and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-09-16 | — | — | CN | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153629-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| EP-2057168-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008028141-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063066-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | CREBBP 424/4885TDP1 1691/4885NOS1 3738/4885 |
| US-20100234370-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3R1 | CREBBP 1066/4885TDP1 647/4885NOS1 1388/4885 |
| US-20100120846-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | CREBBP 2045/4885TDP1 2337/4885NOS1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.